This is a firm fixed price delivery order awarded by the Department of Veterans Affairs (VA) to Telix Pharmaceuticals US Inc., a global biopharmaceutical company that develops diagnostic and therapeutic products using targeted radiation. The contract, valued at $316,800.00, is for the supply of Telix's radiopharmaceutical product Illuccix for prostate cancer imaging and Gozetotide for other nuclear medicine procedures to VA medical facilities across the country.
The award is issued under Telix's existing Blanket Purchase Agreement (BPA) with the VA National Acquisition Center, a $17.5 million BPA awarded in 2022 for the procurement of Illuccix through 2024. Telix also holds a separate $4.55 million BPA with VHA's VISN 9 network for various radiopharmaceuticals to support the VA's medical imaging needs. These contract vehicles allow the VA to efficiently procure Telix's radiopharmaceutical products to fulfill imaging and nuclear medicine requirements across its healthcare system serving veterans. The contract has no set-aside designation.
Generated 2/5/25, 9:28 AM